DAI (DLM-1/ZBP1) as a Genetic Adjuvant for DNA Vaccines That Promotes Effective Antitumor CTL Immunity
Open Access
- 1 March 2011
- journal article
- research article
- Published by Elsevier in Molecular Therapy
- Vol. 19 (3), 594-601
- https://doi.org/10.1038/mt.2010.268
Abstract
No abstract availableKeywords
This publication has 50 references indexed in Scilit:
- Optimization of Skin Electroporation in Mice to Increase Tolerability of DNA Vaccine Delivery to PatientsMolecular Therapy, 2009
- RNA Polymerase III Detects Cytosolic DNA and Induces Type I Interferons through the RIG-I PathwayCell, 2009
- RIG-I-dependent sensing of poly(dA:dT) through the induction of an RNA polymerase III–transcribed RNA intermediateNature Immunology, 2009
- Adoptive cell therapy for the treatment of patients with metastatic melanomaCurrent Opinion in Immunology, 2009
- AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASCNature, 2009
- DNA vaccines: precision tools for activating effective immunity against cancerNature Reviews Cancer, 2008
- TANK-binding kinase-1 delineates innate and adaptive immune responses to DNA vaccinesNature, 2008
- Recognition of microorganisms and activation of the immune responseNature, 2007
- GM-CSF DNA: An adjuvant for higher avidity IgG, rectal IgA, and increased protection against the acute phase of a SHIV-89.6P challenge by a DNA/MVA immunodeficiency virus vaccineVirology, 2007
- DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune responseNature, 2007